Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8121914 | 0.92 | MMP2 (0.83) | MMP2PTGS2PTGS1CHRNA7PDPK1 | |
| SCHEMBL8112683 | 0.91 | PTGS2 (0.69) | MMP2PTGS2PTGS1CHRNA7PDPK1 | |
| SCHEMBL20042406 | 0.91 | MMP2 (0.84) | MMP2PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL8421818 | 0.90 | PTGS2 (0.71) | MMP2PTGS2PTGS1CHRNA7CYP2C9 | |
| SCHEMBL8120987 | 0.90 | PTGS2 (0.67) | MMP2PTGS2PTGS1CHRNA7PDPK1 | |
| SCHEMBL8111717 | 0.90 | PTGS2 (0.67) | MMP2PTGS2PTGS1CHRNA7PDPK1 | |
| SCHEMBL8122502 | 0.89 | PTGS2 (0.69) | MMP2PTGS2PTGS1CHRNA7PDPK1 | |
| SCHEMBL18180816 | 0.89 | CYP2C9 (0.77) | MMP2PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL20042405 | 0.89 | MMP2 (0.70) | MMP2PTGS2PTGS1CHRNA7PDPK1 | |
| SCHEMBL8125055 | 0.88 | PTGS2 (0.62) | MMP2PTGS2PTGS1CHRNA7PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| US-11202773-B2 | Locally bioavailable drugs | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-21 | — | — | US | disclosed |
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-04-12 | — | — | US | disclosed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | disclosed |
| EP-1058559-B1 | COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR | MERCK SHARP & DOHME (GB) | 2004-05-12 | — | — | EP | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| EP-1283723-A2 | COMBINATION THERAPY USING COX-2 SELECTIVE INHIBITOR AND THROMBOXANE INHIBITOR AND COMPOSITIONS THEREFOR | Merck Frosst Canada & Co. (CA) | 2003-02-19 | — | — | EP | disclosed |
| US-6511968-B1 | COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of aspirin; does not contain HMG-CoAreductase inhibitor | MERCK & CO., INC. | 2003-01-28 | — | — | US | disclosed |
| US-6440967-B1 | Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1058559-A1 | COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR | MERCK SHARP & DOHME LTD. (GB) | 2000-12-13 | — | — | EP | disclosed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | disclosed |
| EP-0731796-B1 | 1,3,5-TRISUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-2000027382-A2 | COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND COX-2 INHIBITOR, NSAID, ESTROGEN OR VITAMIN E | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000018352-A2 | A METHOD FOR TREATING INFLAMMATORY DISEASES BY ADMINISTERING A THROMBIN INHIBITOR | MERCK & CO., INC. (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999044640-A1 | COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR | MERCK SHARP & DOHME LIMITED (GB) | 1999-09-10 | — | — | WO | disclosed |
| EP-0731796-A1 | 1,3,5-TRISUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5434178-A | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation | G.D. SEARLE & CO. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995015318-A1 | 1,3,5-TRISUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | ABCG2, FABP1, FABP2 | MMP2 1054/4885PTGS2 3366/4885PTGS1 3087/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | MMP2 1261/4885PTGS2 2/4885PTGS1 1/4885 |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | BPGM, PLG, FGB | MMP2 483/4885PTGS2 372/4885PTGS1 206/4885 |
| US-11202773-B2 | Locally bioavailable drugs | ABCG2, FABP1, FABP2 | MMP2 1054/4885PTGS2 3366/4885PTGS1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.